Rigel Pharmaceuticals (RIGL) Return on Invested Capital (2021 - 2026)

Rigel Pharmaceuticals' Return on Invested Capital history runs 5 years deep, the most recent figure standing at 0.01% for Q1 2026.

• In Q1 2026, Return on Invested Capital fell 1.0% year-over-year to 0.01%; the TTM figure through Mar 2026 stood at 0.01% (down 1.0% YoY), while the FY2025 annual figure was 0.02%, up 6.0% from the prior year.
• Return on Invested Capital was 0.01% for Q1 2026 at Rigel Pharmaceuticals, down from 0.01% in the prior quarter.
• In the past five years, Return on Invested Capital ranged from a high of 0.07% in Q3 2022 to a low of 0.51% in Q2 2022.
• Historically, Return on Invested Capital has averaged 0.06% across 4 years, with a median of 0.01% in 2025.
• The sharpest annual moves came in 2022 and 2025: Return on Invested Capital tumbled 51 bps in 2022, then increased 13 bps in 2025.
• A 4-year view of Return on Invested Capital shows it stood at 0.07% in 2022, then tumbled by 268 bps to 0.11% in 2024, then surged by 112 bps to 0.01% in 2025, then sank by 34 bps to 0.01% in 2026.
• The last three Return on Invested Capital figures came in at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025), per Business Quant data.